A retrospective multicenter study of fatal pediatric melanoma.


Journal

Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 22 04 2020
revised: 23 06 2020
accepted: 29 06 2020
pubmed: 6 7 2020
medline: 10 4 2021
entrez: 5 7 2020
Statut: ppublish

Résumé

Pediatric melanoma is rare and diagnostically challenging. To characterize clinical and histopathologic features of fatal pediatric melanomas. Multicenter retrospective study of fatal melanoma cases in patients younger than 20 years diagnosed between 1994 and 2017. Of 38 cases of fatal pediatric melanoma identified, 57% presented in white patients and 19% in Hispanic patients. The average age at diagnosis was 12.7 years (range, 0.0-19.9 y), and the average age at death was 15.6 years (range, 1.2-26.2 y). Among cases with known identifiable subtypes, 50% were nodular (8/16), 31% were superficial spreading (5/16), and 19% were spitzoid melanoma (3/16). One fourth (10/38) of melanomas arose in association with congenital melanocytic nevi. Retrospective nature, cohort size, and potential referral bias. Pediatric melanoma can be fatal in diverse clinical presentations, including a striking prevalence of Hispanic patients compared to adult disease, and with a range of clinical subtypes, although no fatal cases of spitzoid melanoma were diagnosed during childhood.

Sections du résumé

BACKGROUND BACKGROUND
Pediatric melanoma is rare and diagnostically challenging.
OBJECTIVE OBJECTIVE
To characterize clinical and histopathologic features of fatal pediatric melanomas.
METHODS METHODS
Multicenter retrospective study of fatal melanoma cases in patients younger than 20 years diagnosed between 1994 and 2017.
RESULTS RESULTS
Of 38 cases of fatal pediatric melanoma identified, 57% presented in white patients and 19% in Hispanic patients. The average age at diagnosis was 12.7 years (range, 0.0-19.9 y), and the average age at death was 15.6 years (range, 1.2-26.2 y). Among cases with known identifiable subtypes, 50% were nodular (8/16), 31% were superficial spreading (5/16), and 19% were spitzoid melanoma (3/16). One fourth (10/38) of melanomas arose in association with congenital melanocytic nevi.
LIMITATIONS CONCLUSIONS
Retrospective nature, cohort size, and potential referral bias.
CONCLUSIONS CONCLUSIONS
Pediatric melanoma can be fatal in diverse clinical presentations, including a striking prevalence of Hispanic patients compared to adult disease, and with a range of clinical subtypes, although no fatal cases of spitzoid melanoma were diagnosed during childhood.

Identifiants

pubmed: 32622142
pii: S0190-9622(20)32110-1
doi: 10.1016/j.jaad.2020.06.1010
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1274-1281

Informations de copyright

Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Auteurs

Elena B Hawryluk (EB)

Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Boston Children's Hospital, Boston, Massachusetts. Electronic address: ehawryluk@partners.org.

Danna Moustafa (D)

Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.

Diana Bartenstein (D)

Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Boston Children's Hospital, Boston, Massachusetts.

Meera Brahmbhatt (M)

Emory University School of Medicine, Department of Dermatology, Atlanta, Georgia.

Kelly Cordoro (K)

University of California-San Francisco Benioff Children's Hospital, San Francisco, California; Department of Dermatology, University of California, San Francisco, San Francisco, California.

Laura Gardner (L)

Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah.

Abigail Gauthier (A)

University of Alabama at Birmingham School of Medicine, Birmingham, Alabama.

Douglas Grossman (D)

Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

Deepti Gupta (D)

Department of Dermatology, Seattle Children's Hospital, Seattle, Washington; University of Washington School of Medicine, Seattle, Washington.

Raegan D Hunt (RD)

Department of Dermatology, Texas Children's Hospital, Houston, Texas; Baylor College of Medicine, Houston, Texas.

Melinda Jen (M)

Department of Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.

Pei-Chi Kao (PC)

Harvard Medical School, Boston, Massachusetts; Boston Children's Hospital, Boston, Massachusetts; Dana-Farber Cancer Institute, Boston, Massachusetts.

Lacey L Kruse (LL)

Department of Dermatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Leslie P Lawley (LP)

Emory University School of Medicine, Department of Dermatology, Atlanta, Georgia.

Wendy B London (WB)

Harvard Medical School, Boston, Massachusetts; Boston Children's Hospital, Boston, Massachusetts; Dana-Farber Cancer Institute, Boston, Massachusetts.

Danny Mansour (D)

The Hospital for Sick Children, Toronto, Canada; University of Toronto, Toronto, Canada.

Judith A O'Haver (JA)

Phoenix Children's Hospital, Department of Dermatology, Phoenix, Arizona.

Thuy Phung (T)

Department of Dermatology, Texas Children's Hospital, Houston, Texas; Baylor College of Medicine, Houston, Texas.

Elena Pope (E)

The Hospital for Sick Children, Toronto, Canada; University of Toronto, Toronto, Canada.

Harper N Price (HN)

Phoenix Children's Hospital, Department of Dermatology, Phoenix, Arizona.

Tova Rogers (T)

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Skin Cancer Center, New York, New York.

Sonal D Shah (SD)

University of California-San Francisco Benioff Children's Hospital, San Francisco, California; Department of Dermatology, University of California, San Francisco, San Francisco, California.

Zachary Wolner (Z)

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Skin Cancer Center, New York, New York.

Jennifer Huang (J)

Harvard Medical School, Boston, Massachusetts; Boston Children's Hospital, Boston, Massachusetts.

Ashfaq A Marghoob (AA)

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Skin Cancer Center, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH